384 related articles for article (PubMed ID: 947194)
1. Importance of biopharmaceutics and pharmacokinetics in clinical medicine.
Cabana BE
Arzneimittelforschung; 1976; 26(1A):151-8. PubMed ID: 947194
[TBL] [Abstract][Full Text] [Related]
2. [Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)].
Schnieders B
Arzneimittelforschung; 1976; 26(1A):158-63. PubMed ID: 947195
[TBL] [Abstract][Full Text] [Related]
3. An overview of the analysis and interpretation of bioavailability studies in man.
Wagner JG
Arzneimittelforschung; 1976; 26(1A):105-8. PubMed ID: 947190
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of drugs: principles and problems. Report of a WHO Scientific Group.
World Health Organ Tech Rep Ser; 1973 Nov; 536():1-17. PubMed ID: 4204708
[No Abstract] [Full Text] [Related]
5. [The role of biopharmaceutical parameters in drug development (author's transl)].
Thoma K
Arzneimittelforschung; 1976; 26(1A):121-9. PubMed ID: 947191
[TBL] [Abstract][Full Text] [Related]
6. [Absorption and biological availability of drugs].
Uribe M
Rev Gastroenterol Mex; 1977; 42(1):2-8. PubMed ID: 616972
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the clinical inequivalency of drug products of varying bioavailability.
Barr WH; Adir J
Ann Clin Res; 1974; 6(0):suppl 11:48-56. PubMed ID: 4605465
[No Abstract] [Full Text] [Related]
8. The general problem of drug bioavailability and its assessment in man.
Smith RN
Postgrad Med J; 1974 Nov; 50 Suppl 6():7-14. PubMed ID: 4459894
[No Abstract] [Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability and pharmacokinetic analysis of drug responding systems.
Smolen VF
Annu Rev Pharmacol Toxicol; 1978; 18():495-522. PubMed ID: 348066
[No Abstract] [Full Text] [Related]
11. Primer on clinical pharmacokinetics.
Bauer LA
Am J Hosp Pharm; 1983 Oct; 40(10):1637-41. PubMed ID: 6638025
[TBL] [Abstract][Full Text] [Related]
12. Bioavailability of peroral dosage forms.
Ritschel WA
Boll Chim Farm; 1973 Mar; 112(3):137-62. PubMed ID: 4198518
[No Abstract] [Full Text] [Related]
13. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
Mishra V; Gupta U; Jain NK
Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
[TBL] [Abstract][Full Text] [Related]
14. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends.
Srinivas NR
Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891
[TBL] [Abstract][Full Text] [Related]
15. [Bioavailability of drug products and bioequivalence requirements (author's transl)].
Jaminet F
J Pharm Belg; 1978; 33(3):141-56. PubMed ID: 682101
[No Abstract] [Full Text] [Related]
16. [Clinical problems of optimum bioavailability, in particular in cytostatic therapy (author's transl)].
Gross R; Hirschmann WD
Arzneimittelforschung; 1976; 26(1A):130-5. PubMed ID: 947192
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and bioavailability.
Wagner JG
Triangle; 1975; 14(3-4):101-8. PubMed ID: 1209729
[No Abstract] [Full Text] [Related]
18. In vitro - in vivo correlation: from theory to applications.
Emami J
J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
[TBL] [Abstract][Full Text] [Related]
19. Bioavailability studies and the clinical pharmacologist: correlation of drug distribution with clinical effects.
Ogilvie RI
Int J Clin Pharmacol Biopharm; 1975 Jun; 11(4):349-54. PubMed ID: 1099026
[TBL] [Abstract][Full Text] [Related]
20. [Clinical value of the determination of drugs in the blood: a new aspect of pharmacokinetics].
Hirtz J; Schoeller JP
Nouv Presse Med; 1976 Mar; 5(13):869-72. PubMed ID: 1264634
[No Abstract] [Full Text] [Related]
[Next] [New Search]
